Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician's desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS tests. The company also provides Lens, a software application for life sciences and advanced precision research; diagnostics services, such as NGS diagnostics, PCR profiling, and other anatomic and molecular pathology tests; and large-panel solid tumor and hematologic testing through multiple assays, with its core clinical assay (xT and xR) offering large panel DNA, RNA full transcriptome, and incidental germline findings through normal blood or saliva analyses. In addition, it provides genetic tests focused on inherited conditions; an nP assay for pharmacogenomic testing for patients with psychiatric conditions, including depression, general anxiety disorder, bipolar disorder, and other relevant diagnoses; Insights, which licenses libraries of linked, de-identified clinical, molecular, and imaging data; Organoids, a tumor derived biological modeling. Further, the company offers Trials for clinical trial matching services; Next, an AI platform; Algos, an algorithm-based diagnostics application. It has Strategic Collaborations with AstraZeneca AB, Pathos AI, Inc., GlaxoSmithKline, Merck, and Recursion Pharmaceuticals, Inc. Additionally, it also has a strategic collaboration with Blood Cancer United to develop registry for pediatric acute myeloid leukemia. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023. Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.

NASDAQHealthcareMedical - Healthcare Information Services
最新資料
US$70.93
+US$1.65 · +2.38%
前收盤價
US$70.93
+US$1.65 · +2.38%
盤中時間採用ET。市場資料可能有所延遲。
Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician's desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS tests. The company also provides Lens, a software application for life sciences and advanced precision research; diagnostics services, such as NGS diagnostics, PCR profiling, and other anatomic and molecular pathology tests; and large-panel solid tumor and hematologic testing through multiple assays, with its core clinical assay (xT and xR) offering large panel DNA, RNA full transcriptome, and incidental germline findings through normal blood or saliva analyses. In addition, it provides genetic tests focused on inherited conditions; an nP assay for pharmacogenomic testing for patients with psychiatric conditions, including depression, general anxiety disorder, bipolar disorder, and other relevant diagnoses; Insights, which licenses libraries of linked, de-identified clinical, molecular, and imaging data; Organoids, a tumor derived biological modeling. Further, the company offers Trials for clinical trial matching services; Next, an AI platform; Algos, an algorithm-based diagnostics application. It has Strategic Collaborations with AstraZeneca AB, Pathos AI, Inc., GlaxoSmithKline, Merck, and Recursion Pharmaceuticals, Inc. Additionally, it also has a strategic collaboration with Blood Cancer United to develop registry for pediatric acute myeloid leukemia. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023. Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.
日內區間
目前US$70.93
52週區間
目前US$70.93
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目(USD) | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 12.72億 USD | 6.93億 USD | 5.32億 USD | 3.21億 USD | 2.58億 USD |
| 銷貨成本 | 4.74億 USD | 3.12億 USD | 2.46億 USD | 1.9億 USD | 1.74億 USD |
| 毛利 | 7.98億 USD | 3.81億 USD | 2.86億 USD | 1.3億 USD | 8364.4萬 USD |
| 研究與開發 | 3.19億 USD | 3.17億 USD | 1.85億 USD | 1.62億 USD | 1.28億 USD |
| 銷售、一般及管理費用 | 7.15億 USD | 7.55億 USD | 2.97億 USD | 2.33億 USD | 1.99億 USD |
| 營業費用 | 10.51億 USD | 10.72億 USD | 4.82億 USD | 3.96億 USD | 3.27億 USD |
| 利息收入 | 1262.8萬 USD | 1108.4萬 USD | 760.1萬 USD | 303.2萬 USD | 62.3萬 USD |
| 利息支出 | 7026.7萬 USD | 5365.3萬 USD | 4686.9萬 USD | 2189.4萬 USD | 1518.4萬 USD |
| 折舊和攤銷 | 1.02億 USD | 3724.5萬 USD | 3333.2萬 USD | 3041萬 USD | 2388.1萬 USD |
| 營業利益 | −2.53億 USD | −6.91億 USD | −1.96億 USD | −2.65億 USD | −2.44億 USD |
| 淨利 | −2.45億 USD | −7.06億 USD | −2.14億 USD | −2.9億 USD | −2.59億 USD |
公司資料更新於 2026年10月11日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動,並非 GoAI 建議。
平均目標
US$72.60
上漲空間 2.35%報告持有此股票曝險的交易所交易基金。
ARK Innovation ETFARKK3.44億5.00%55.62億 USD0.75%US$89.62+2.31%
Vanguard Morningstar Total Stock Market ETFVTI2.28億0.01%2.3兆 USD0.03%US$381.94+0.63%
ARK Genomic Revolution ETFARKG1.7億8.30%15.57億 USD0.75%US$51.30+4.08%
Vanguard Morningstar Small-Cap ETFVB1.65億0.09%1853億 USD0.03%US$289.48+0.64%
Vanguard Morningstar Small-Cap Growth ETFVBK9447.17萬0.21%447億 USD0.05%US$344.74+1.22%
Vanguard Extended Market ETFVXF7549.6萬0.08%954億 USD0.05%US$235+0.80%
iShares Biotechnology ETFIBB5780.52萬0.55%108.2億 USD0.44%US$206.49+3.00%
JPMorgan U.S. Tech Leaders ETFJTEK5215.66萬1.06%48.99億 USD0.65%US$107.91+1.80%
ARK Innovation ETFARKK
Vanguard Morningstar Total Stock Market ETFVTI
ARK Genomic Revolution ETFARKG
Vanguard Morningstar Small-Cap ETFVB
Vanguard Morningstar Small-Cap Growth ETFVBK
Vanguard Extended Market ETFVXF
iShares Biotechnology ETFIBB
JPMorgan U.S. Tech Leaders ETFJTEKAI 生成內容及延遲市場資料僅供資訊與教育用途,不構成投資建議。